New Drugs
| Brand/Generic | Company | Description |
|---|---|---|
|
Alhemo concizumab |
Novo Nordisk Canada | A new anti-tissue factor pathway inhibitor antibody for hemophilia B. |
|
Beyfortus nirsevimab |
AstraZeneca/Sanofi | A new long-acting antibody for the prevention of respiratory syncytial virus (RSV) in neonates, infants, and children up to 24 months of age. |
|
Carvykti ciltacabtagene autoleucel |
Janssen | A new B-cell maturation antigen (BCMA)-directed T-cell IV immunotherapy for adults with multiple myeloma. |
|
Columvi glofitamab |
Hoffmann-La Roche | A new CD20/CD-3 binding monoclonal antibody for B-cell lymphoma. |
|
Kengrexal cangrelor |
Methapharm | A new IV direct P2Y12 platelet receptor inhibitor for patients with coronary artery disease undergoing percutaneous coronary intervention (PCI). |
|
Quviviq daridorexant |
Idorsia/Innomar Strategies | A new oral dual orexin receptor antagonist for insomnia in adults. |
|
Spevigo spesolimab |
Boehringer Ingelheim Canada | A new interleukin-36 inhibitor for generalized pustular psoriasis. |
|
Vegzelma bevacizumab |
Celltrion | A biosimilar to Avastin. |
|
Verquvo vericiguat |
Bayer | A new oral soluble guanylate cyclase (sGC) stimulator for symptomatic heart failure with reduced ejection fraction (HFrEF) in adults. |
| Brand/Generic | Company | Description |
|---|---|---|
|
Calquence acalabrutinib maleate |
AstraZeneca | New tablet dosage form that does not interact with gastric acid reducing agents |
|
Ferriprox MR deferiprone |
Chiesi Canada | New extended-release tablet that allows for twice daily dosing. |
|
Zoryve roflumilast |
Arcutis Biotherapeutics | New topical cream for plaque psoriasis. |
| Brand/Generic | Company | Description |
|---|